Wells Fargo’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-58,882
| Closed | -$223K | – | 7192 |
|
|
2020
Q1 | $223K | Sell |
58,882
-97,264
| -62% | -$419K | ﹤0.01% | 4614 |
|
|
2019
Q4 | $795K | Buy |
156,146
+41,668
| +36% | +$220K | ﹤0.01% | 4011 |
|
|
2019
Q3 | $579K | Buy |
114,478
+1,305
| +1% | +$6.51K | ﹤0.01% | 4269 |
|
|
2019
Q2 | $698K | Sell |
113,173
-459,192
| -80% | -$2.21M | ﹤0.01% | 4151 |
|
|
2019
Q1 | $2.66M | Buy |
572,365
+458,070
| +401% | +$2.07M | ﹤0.01% | 3118 |
|
|
2018
Q4 | $481K | Buy |
114,295
+3,517
| +3% | +$17.9K | ﹤0.01% | 4362 |
|
|
2018
Q3 | $695K | Buy |
110,778
+3,777
| +4% | +$29K | ﹤0.01% | 4217 |
|
|
2018
Q2 | $860K | Sell |
107,001
-73,756
| -41% | -$563K | ﹤0.01% | 4104 |
|
|
2018
Q1 | $1.35M | Sell |
180,757
-33,866
| -16% | -$225K | ﹤0.01% | 3679 |
|
|
2017
Q4 | $1.28M | Buy |
214,623
+5,807
| +3% | +$35.3K | ﹤0.01% | 3751 |
|
|
2017
Q3 | $1.54M | Buy |
208,816
+44,658
| +27% | +$284K | ﹤0.01% | 3507 |
|
|
2017
Q2 | $1.11M | Sell |
164,158
-22,654
| -12% | -$167K | ﹤0.01% | 3661 |
|
|
2017
Q1 | $1.76M | Sell |
186,812
-13,646
| -7% | -$136K | ﹤0.01% | 3312 |
|
|
2016
Q4 | $1.73M | Buy |
200,458
+127,142
| +173% | +$940K | ﹤0.01% | 3271 |
|
|
2016
Q3 | $464K | Buy |
73,316
+360
| +0.5% | +$2.18K | ﹤0.01% | 3996 |
|
|
2016
Q2 | $308K | Sell |
72,956
-5,700
| -7% | -$27.5K | ﹤0.01% | 4171 |
|
|
2016
Q1 | $343K | Buy |
78,656
+3,086
| +4% | +$13.7K | ﹤0.01% | 4096 |
|
|
2015
Q4 | $463K | Buy |
75,570
+55,803
| +282% | +$366K | ﹤0.01% | 3972 |
|
|
2015
Q3 | $113K | Sell |
19,767
-17,088
| -46% | -$131K | ﹤0.01% | 4799 |
|
|
2015
Q2 | $276K | Buy |
36,855
+31,332
| +567% | +$190K | ﹤0.01% | 4426 |
|
|
2015
Q1 | $33K | Buy |
5,523
+2,297
| +71% | +$14.5K | ﹤0.01% | 5182 |
|
|
2014
Q4 | $24K | Buy |
3,226
+26
| +0.8% | +$156 | ﹤0.01% | 5291 |
|
|
2014
Q3 | $17K | Sell |
3,200
-3,154
| -50% | -$15.7K | ﹤0.01% | 5383 |
|
|
2014
Q2 | $27K | Buy |
+6,354
| New | +$24.3K | ﹤0.01% | 5240 |
|
Other funds holding PGNX
Wells Fargo's PGNX Position: Q2 2020 in Review
Wells Fargo sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 58,882 shares — an estimated $223K sold.
Wells Fargo first reported a position in PGNX in Q2 2014 and held it in 24 quarters. The position peaked at $2.66M in Q1 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Wells Fargo reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Wells Fargo sold 58,882 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $223K.
- Wells Fargo first reported a position in Progenics Pharmaceuticals Inc in Q2 2014 and held it in 24 quarters.
- Wells Fargo's Progenics Pharmaceuticals Inc position peaked at $2.66M in Q1 2019.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Wells Fargo's 13F filing for Q2 2020, filed 13 Aug 2020.